CommercialCoverageMedium impact
BlueSpeak September 2026: Medical Policy Updates
Blue Cross and Blue Shield of Kansas City·Neurosurgery, Oncology, Urology +3 more·Medical Policy
Effective date
Oct 1, 2026
We identified it
Sep 29, 2026
Summary
Blue KC issued five new medical policies effective October 1, 2026, classifying several procedures and diagnostic tools as investigational: genicular artery embolization for knee osteoarthritis, navigated transcranial magnetic stimulation for brain surgery mapping, eye-tracking diagnostic aids for autism, mammography-based AI risk prediction models, and the Optilume device for urethral stricture (with limited exception) and benign prostatic hyperplasia. These policies will require claims denial or prior authorization updates for affected procedures.
Action Required
By September 15, 2026: Billing team must update claims processing system to flag or deny claims for the following investigational procedures effective 10/1/2026: (1) Genicular artery embolization (GAE) for osteoarthritis of the knee using any embolic agent; (2) Navigated transcranial magnetic stimulation (nTMS) for preoperative brain mapping; (3) Eye-tracking diagnostic devices for autism spectrum disorder assessment; (4) Mammography-based AI risk prediction software for breast cancer risk assessment; (5) Optilume BPH Catheter System for benign prostatic hyperplasia (exception: Optilume Urethral drug-coated balloon is covered only for recurrent anterior urethral stricture meeting all specified criteria). Providers should be notified that claims for these services will be denied as investigational unless prior authorization is obtained and medical necessity criteria are met. Update denial templates and encounter forms accordingly. Contact Blue KC provider relations for specific prior authorization processes if required.